MMQCI

What MMQCI does

Maine Molecular Quality Controls, Inc. (MMQCI) is a privately held, founder-owned specialty manufacturer of external quality control products for molecular diagnostic testing, headquartered and produced at an ISO 13485:2016 / MDSAP-certified cGMP facility in Saco, Maine. Founded in January 2000 by Joan Gordon (President/CEO) and Dr. Clark Rundell (VP Research) — both formerly of Maine Medical Center — the company builds its products on Rundell's patented process for stabilizing target nucleic acid constructs, yielding synthetic, non-infectious, multiplex DNA/RNA controls suspended in a defined matrix. The portfolio spans three brands (INTROL assayed controls, Birlinn platform-agnostic unassayed controls, and platform-specific SKUs) covering infectious disease (respiratory panels, GI, blood culture ID, meningitis/encephalitis, TB, tropical fever, Ebola), inherited disease (cystic fibrosis CFTR panels including NGS workflows, thrombophilia FII/FV Leiden/MTHFR, hereditary hemochromatosis), and oncology (BCR-ABL p210/p190 with WHO-traceable IS reporting, NPM1, PML-RARA, bladder cancer), with deep instrument compatibility across BioFire FilmArray, Roche cobas eplex, Cepheid GeneXpert, QIAGEN QIAstat-Dx, Diasorin LIAISON PLEX/Verigene, Hologic Panther Fusion, Abbott Alinity, and BD Max systems.

MMQCI operates a B2B enterprise sales motion targeting clinical laboratories and molecular diagnostic facilities globally, accepting orders via web form, email, phone, and fax with Net 30 terms and shipping to 60+ countries across 5 continents through direct sales and local distributors. Products are sold as one-time consumable purchases (typical 18-36 month shelf life) at quote-based pricing with annual February price-list updates, and are offered as either IVD (FDA-cleared / CE-IVD) or RUO depending on regulatory status and customer region. The company maintains a close co-development relationship with bioMérieux (parent of BioFire Diagnostics) and is funded exclusively through operating cash flow and early-stage grants from the National Institutes of Health and Maine Technology Institute, with no institutional equity capital. With a sub-10 employee headcount and a 25-year operating history, MMQCI exemplifies a durable, founder-led niche specialty life-sciences manufacturer.

Name

MMQCI

Legal name

Maine Molecular Quality Controls, Inc.

Website

https://mmqci.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

MMQCI is a privately held manufacturer of synthetic, non-infectious external quality controls for molecular diagnostic testing, serving clinical laboratories globally across infectious, inherited, and oncology disease applications on BioFire, Roche, GeneXpert, QIAGEN, Diasorin, and other major molecular platforms.

Ownership category

akta.pro rank

Product category

Molecular Diagnostic Quality Controls (IVD medical device reagents)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

akta.pro secondary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Molecular diagnostic controls
• IVD quality controls
• Infectious disease testing
• Inherited disease testing
• Oncology molecular testing

Headquarters

HQ city

Saco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Molecular Quality Control Products: One-time purchase of quality control products used in molecular diagnostic testing. Controls are consumables with typical shelf life of 18-36 months from date of manufacture. Products available as IVD (In Vitro Diagnostic) or RUO (Research Use Only) depending on regulatory status and customer region.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

MMQCI manufactures and sells external quality control (QC) products for clinical molecular diagnostic testing. The product line consists of synthetic, non-infectious nucleic-acid control panels used by clinical laboratories to monitor the performance of molecular assays for inherited disease (cystic fibrosis, thrombophilia, hereditary hemochromatosis), infectious disease (respiratory, gastrointestinal, bloodstream, meningitis/encephalitis, tuberculosis, tropical fever, Ebola, SARS-CoV-2/influenza/RSV), and oncology (BCR-ABL, NPM1, PML-RARA, bladder cancer) on major platforms including BioFire FilmArray, Roche cobas eplex, Cepheid GeneXpert, QIAGEN QIAstat-Dx, Diasorin LIAISON PLEX/Verigene, Hologic Panther Fusion, Abbott Alinity, and BD Max.

Product overview

MMQCI (Maine Molecular Quality Controls) is a manufacturer of external quality control products for molecular diagnostic testing. The portfolio consists of multiple product lines organized by testing category and platform compatibility: (1) BioFire Controls for BIOFIRE FILMARRAY systems including RP2.1/RP2.1plus, GI, BCID2, Pneumonia, JI, ME, Ebola, TF, and SPOTFIRE/RSP panels; (2) ePlex Controls for Roche cobas eplex systems covering RP, RP2, RP3, BCID-FP, BCID-GP, and BCID-GN panels; (3) GeneXpert Controls for Cepheid systems including TB panels (M110, M114, M114plus, TB-XDR, TBNEG-30), SARS-CoV-2, Carba-R, FII/FV, and oncology panels (BCR-ABL, NPM1, PML-RARA, Bladder Cancer); (4) QIAstat-Dx Controls for QIAGEN systems; (5) LIAISON PLEX and Verigene Controls for Diasorin systems; (6) Birlinn unassayed Controls compatible with most platforms and LDTs for CoV2-Flu-RSV, HH Panel, and BCR-ABL p210; (7) CF Testing Controls (INTROL CF Panels I/II/III and NGS CF Panels); (8) Oncology Testing Controls (BCR-ABL IS Panels, NPM1, PML-RARA, Bladder Cancer); and (9) Thrombosis Genotype Panels. The products are manufactured under ISO 13485:2016 and MDSAP certifications.

Differentiator

Problem solved

Functional benefit

Brands

• Birlinn: Unassayed controls compatible with most platforms and LDTs. The name is anchored in Scottish Gaelic for swift, stalwart Viking ship. Birlinn controls feature large sequence coverage and lot-to-lot consistency tested over multiple sites, instruments, operators, and cartridge lots.
• INTROL

Products and services

• BioFire® RP2.1/RP2.1plus Control Panel M441 External quality control for the BioFire RP2.1/RP2.1plus Respiratory Panel on FilmArray systems, monitoring detection of respiratory pathogens. Used by clinical molecular diagnostics laboratories.
• FilmArray® GI Control Panel M238 External quality control for the BioFire FILMARRAY Gastrointestinal (GI) Panel, monitoring detection of 22 gastrointestinal pathogens. Used by clinical microbiology laboratories performing syndromic GI testing.
• FilmArray® BCID2 Control Panel M416 External quality control for the FilmArray BCID2 Blood Culture Identification Panel, monitoring detection of gram-positive and gram-negative bacteria, resistance genes, and yeast. Developed in close collaboration with bioMérieux/BioFire.
• FilmArray® Pneumonia/Pneumonia plus Control M340 External quality control for the FilmArray Pneumonia/Pneumonia plus Panel, monitoring detection of respiratory viral and bacterial targets for lower respiratory tract infection testing.
• BioFire® JI Control Panel M420 External quality control for the BioFire Joint Infection (JI) Panel on FilmArray systems, monitoring detection of gram-positive and gram-negative bacteria, resistance genes, and yeast in synovial fluid testing.
• BioFire® ME Control Panel M262 External quality control for the BioFire Meningitis/Encephalitis (ME) Panel on FilmArray systems, monitoring detection of pathogens in cerebrospinal fluid.
• FilmArray® Ebola Control Panel M251 Quality control for presumptive detection of Ebola Zaire virus on the FilmArray BioThreat-E test.
• FilmArray® TF Control Panel M527 External quality control for the BioFire FILMARRAY Tropical Fever Panel, monitoring detection of Chikungunya virus, Dengue virus, Plasmodium spp., Plasmodium falciparum, Plasmodium vivax/ovale, and Leptospira spp. on the BIOFIRE FILMARRAY 2.0 or Torch systems.
• SPOTFIRE® RSP Pos & Neg Controls M425 External quality control for the BIOFIRE SPOTFIRE Respiratory Panel (and variants) on the SPOTFIRE System.
• eplex RP Control M306 External quality control for the cobas eplex Respiratory Pathogen (RP) Panel on the Roche cobas eplex system.
• eplex RP2 Control M451 External quality control for the cobas eplex Respiratory Pathogen Panel 2 (RP2) on the Roche cobas eplex system.
• eplex RP3 Control M530 External quality control for the cobas eplex Respiratory Pathogen Panel 3 (RP3) on the Roche cobas eplex system.
• eplex BCID-FP Control M320v1.1 External quality control for the cobas eplex Blood Culture Identification Fungal Pathogen (BCID-FP) Panel on the Roche cobas eplex system.
• eplex BCID-GP Control M323v1.1 External quality control for the cobas eplex Blood Culture Identification Gram-Positive (BCID-GP) Panel on the Roche cobas eplex system.
• eplex BCID-GN Control M326 External quality control for the cobas eplex Blood Culture Identification Gram-Negative (BCID-GN) Panel on the Roche cobas eplex system.
• Xpert SARS-CoV-2 Control Panel M430 External quality control for the Xpert Xpress CoV-2 plus assay on Cepheid GeneXpert systems.
• Xpert Carba-R QC Panel M219 Quality control for the Xpert Carba-R Assay monitoring detection of carbapenem resistance genes on Cepheid GeneXpert systems.
• INTROL® TB Panel M110 Quality control for molecular detection of Mycobacterium tuberculosis and MDR-TB mutations, intended for clinical TB testing laboratories.
• INTROL® TB Panel M114 Quality control for GeneXpert-based MTB testing, including detection of drug-resistant TB variants.
• INTROL® TB Panel M114plus Quality control for GeneXpert MTB assays verifying detection of MTB and key drug-resistance markers.
• INTROL® TB-XDR Panel M345 Quality control for the Xpert MTB/XDR assay monitoring detection of extensively drug-resistant tuberculosis on Cepheid GeneXpert.
• INTROL® TBNEG-30 Negative control for GeneXpert MTB assays confirming absence of M. tuberculosis DNA.
• QIAstat-Dx RP SARS-CoV-2 Control Panel External quality control for the QIAstat-Dx Respiratory Panel on QIAGEN QIAstat-Dx systems, intended for respiratory pathogen QC.
• QIAstat-Dx GI 2 Control Panel External quality control for the QIAstat-Dx Gastrointestinal Panel 2 on QIAGEN QIAstat-Dx systems.
• LIAISON PLEX RP Control Panel M518 External quality control for the LIAISON PLEX Respiratory Flex Assay on the Diasorin LIAISON PLEX System.
• Verigene® RP Flex Control Panel M270 Quality control for the Verigene Respiratory Pathogen Flex Panel on Diasorin Verigene systems.
• INTROL® CF Panel I Control v.02 Quality control for cystic fibrosis testing, monitoring 38 CFTR mutations including ACMG/ACOG-recommended variants and polymorphisms. Used by clinical genetics laboratories.
• INTROL® CF Panel II Control Quality control for cystic fibrosis testing, monitoring 54 CFTR mutations including ACMG/ACOG-recommended variants.
• INTROL® CF Panel III Control Quality control for cystic fibrosis testing, monitoring 79 CFTR mutations including ACMG/ACOG-recommended variants.
• NGS CF Control Panel G211 v1.1 Quality control for Next Generation Sequencing workflows for the CFTR gene, monitoring insertions, deletions, and homopolymer variants.
• NGS CF Control Panel G211plus Expanded quality control for Next Generation Sequencing workflows for the CFTR gene with broader variant coverage.
• INTROL® Thrombosis Genotype Panel Quality control for Factor II, Factor V Leiden, and MTHFR gene mutations associated with thrombotic events, used in clinical genetics and thrombophilia testing.
• Xpert FII & FV Genotype Panel G109 Quality control for Factor II G20210A and Factor V Leiden G1691A detection on Cepheid GeneXpert systems.
• Birlinn® HH Panel G203 Unassayed control for hereditary hemochromatosis mutations (H63D, S65C, C282Y), compatible with most platforms and LDTs.
• Xpert BCR-ABL IS Panel C130 Assayed external quality control for quantitative detection of BCR-ABL1 p210 translocation transcripts on Cepheid GeneXpert systems, with values for International Scale reporting.
• Xpert BCR-ABL IS p210 Panel C206 Quality control for BCR-ABL1 p210 quantification using the Xpert BCR-ABL Ultra assay on Cepheid GeneXpert systems.
• Xpert BCR-ABL1 p190 Control Panel C183 Reference material for monitoring quantitative detection of the BCR-ABL1 p190 translocation on Cepheid GeneXpert systems.
• Xpert NPM1 Control Panel C194v1.1 Assayed external quality control for quantitative detection of NPM1 mutant transcripts on Cepheid GeneXpert systems.
• Xpert PML-RARA Control Panel C215 Reference material for quantitative detection of PML-RARA transcript isoforms on Cepheid GeneXpert systems.
• Xpert Bladder Cancer Panel C104 Quality control for qualitative detection of bladder cancer RNA transcripts (CRH, IGF2, UPK1B, ANXA10, ABL1) on Cepheid GeneXpert systems.
• Birlinn® CoV2-Flu-RSV Control Panel M509 Unassayed quality control compatible with most platforms and LDTs for monitoring detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus (RSV); compatible with 15+ assays across major molecular platforms.
• Birlinn® BCR-ABL1 p210 IS Panel C230 Unassayed control for BCR-ABL1 p210 with WHO-traceable values for International Scale conversion, compatible with multiple platforms.
• Birlinn® BCR-ABL1 p210 IS Control Panel C240 Unassayed control for BCR-ABL1 p210 monitoring with WHO-traceable values, compatible with multiple platforms.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• bioMérieuxcoreStrategic or Co-development PartnerMMQCI works in close collaboration with bioMérieux to review and optimize formulation of FilmArray BCID2 Positive Control Panel M416. BioMérieux is the parent company of bioFire Diagnostics, manufacturer of the BioFire FilmArray systems for which MMQCI produces quality controls.
• International DistributorscoreChannel Partner/ Reseller/ DistributorMMQCI has local distributors available to support customers in 60+ countries across 5 continents. Controls are classified as medical devices and ship under HS code 3822.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• SeraCare (LGC Clinical Diagnostics): SeraCare, now part of LGC Group, is the most direct comparable: it manufactures reference materials and quality controls (including AccuPlex synthetic molecular controls) used by clinical laboratories to validate molecular diagnostic assays—the same core product category as MMQCI's controls.
• ZeptoMetrix: ZeptoMetrix manufactures external quality controls and reference materials for infectious disease molecular testing, overlapping directly with MMQCI's respiratory, GI, blood culture, and tropical fever product lines.
• Qnostics: Qnostics produces molecular quality controls and external run controls for infectious disease and infectious-molecular assays; it directly competes in the same clinical laboratory QC category MMQCI serves.
• Microbiologics: Microbiologics supplies biological reference materials, controls, and standards used in clinical and molecular microbiology, overlapping with MMQCI's infectious disease QC portfolio for pathogens, TB, and antimicrobial resistance targets.

Broad incumbents

• Bio-Rad Laboratories: Bio-Rad is a broad life-science tools and clinical diagnostics incumbent with a sizable molecular QC and quality controls business; while not a pure-play niche molecular QC vendor like MMQCI, it competes for the same clinical-lab QC budget across molecular and immunology assays.
• bioMérieux: bioMérieux is the parent of BioFire Diagnostics (FilmArray systems), for which MMQCI manufactures multiple control panels under a co-development relationship. As both an OEM partner and a vertically integrated diagnostics company, bioMérieux is the most strategically important adjacent peer.
• Cepheid (Danaher Diagnostics): Cepheid manufactures the GeneXpert systems for which MMQCI produces controls covering TB, SARS-CoV-2, Carba-R, FII/FV, BCR-ABL, NPM1, PML-RARA, and Bladder Cancer assays. It is a critical channel partner and a potential vertical integrator of QC products.
• ELITech Group: ELITech develops and distributes molecular diagnostic instruments and reagents and supplies laboratory quality controls to clinical labs across molecular diagnostics, making it a broader incumbent competing for similar QC wallet share.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mmqci1

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MMQCI